Literature DB >> 2646220

Corticosteroids for the management of ulcerative colitis and Crohn's disease.

D P Jewell1.   

Abstract

Corticosteroids are of proven value for the treatment of active ulcerative colitis and Crohn's disease, but are of little value for the maintenance of remission. The development of new steroid compounds with low systemic bioavailability should allow higher doses to be given for longer periods without risking serious adverse reactions.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2646220

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN： 0889-8553            Impact factor:   3.806


  5 in total

Review 1.  Drug therapy of ulcerative colitis.

Authors:  B Crotty; D P Jewell
Journal:  Br J Clin Pharmacol       Date:  1992-09       Impact factor: 4.335

2.  Does polymeric formula improve adherence to liquid diet therapy in children with active Crohn's disease?

Authors:  A F Rodrigues; T Johnson; P Davies; M S Murphy
Journal:  Arch Dis Child       Date:  2007-05-02       Impact factor: 3.791

3.  Azathioprine reduces extravasation and neutrophil trafficking in immune complex-mediated inflammation in the rat colon.

Authors:  S N Murthy; T Anania; H R Clearfield
Journal:  Agents Actions       Date:  1991-09

4.  Significance of glucocorticoid receptor expression in colonic mucosal cells of patients with ulcerative colitis.

Authors:  Hu Zhang; Qin Ouyang; Zhong-Hui Wen; Claudio Fiocchi; Wei-Ping Liu; Dai-Yun Chen; Feng-Yuan Li
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

5.  Soluble interleukin-2 receptors in ulcerative colitis.

Authors:  O H Nielsen; J Brynskov
Journal:  Mediators Inflamm       Date:  1993       Impact factor: 4.711
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.